database / gh-secretagogue
CJC-1295
also known as modified GRF (1-29)
Skeletal structure drawn from the computed atomic coordinates in PubChem CID 91971820. Carbons are implicit vertices; hydrogens on carbon are suppressed, as in any structural formula. Nothing here is estimated — every atom sits where PubChem placed it.
Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.
Sequence
YADAIFTQSYRKVLAQLSARKLLQDILSR
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
- hydrophobic
- positive
- negative
- polar
- aromatic
- glycine
- proline
- cysteine
Modified molecule. GRF(1-29) analogue with D-Ala2, Gln8, Arg15 and Leu27 substitutions; the DAC version adds a maleimide linker for albumin binding. D-Ala is not representable in one-letter code.
Backbone carries modifications, so computed backbone mass is not comparable to the reported mass of the complete molecule.
Molecular data
| molecular formula | C165H269N47O46 |
|---|---|
| molecular weight | 3647.2 Da (PubChem) |
| computed backbone mass | 3368.93 Da |
| length | 29 residues |
| net charge (pH 7.4) | +3 |
| mean hydropathy | -0.08 |
| half-life | not characterised |
| delivery route | not characterised |
| PubChem CID | 91971820 |
| PDB | not characterised |
| UniProt parent | P01286 |
Mechanism
Growth hormone-releasing hormone analogue acting at GHRH receptors.
Reported targets: GHRHR
Experimental structure
No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.
Helical wheel
Residues projected at 100° per turn, the standard α-helix rotation. Shown because helicity in this peptide is described in the cited literature.
Parent protein
Based on the first 29 residues of GHRH. UniProt P01286 · 108 aa
Reported effects
Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.
| reported outcome | where it appears |
|---|---|
| GH release | Peptide Supplements and Their Therapeutic Applications in Sports Medicine The American journal of sports medicine 2026 |
| IGF-1 elevation | The emerging landscape of performance-enhancing peptides modulating GH-IGF1 … Frontiers in endocrinology 2026 |
Registered trials
| NCT | title | status | phase |
|---|---|---|---|
| NCT00267527 | A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity | TERMINATED | PHASE2 |
Literature (8)
Peptide Supplements and Their Therapeutic Applications in Sports Medicine — The American journal of sports medicine 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 42578445 · DOI 10.1177/03635465261464420
The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Frontiers in endocrinology 2026
Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagogues (GHS; e.g., growth hormone-releasing peptide-2 (GHRP-2), growth hormone-releasing peptide-6 (GHRP-6), hexarelin, ipamorelin), the growth hormone (GH) fragment - AOD9604 (hGH 176-191), and insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)). Reported adverse effects span endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetit…
open access ↗ · PMID 42395176 · DOI 10.3389/fendo.2026.1822475
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — Frontiers in aging 2026
BackgroundPeptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.ObjectiveTo comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions.MethodsA comprehensive narrative review was conducted through systematic searches of PubMed, Scopus, and regulatory databases (FDA, WADA) from inception through January 2026. Search terms included "peptide therapeutics," "aging," "gerontology," "healthspan," combined with specific peptide names (tirzepatide, epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295, ipamorelin, bremelanotide). Peer-reviewed articles, clinical trials, regulatory docume…
open access ↗ · PMID 42021992 · DOI 10.3389/fragi.2026.1790247
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — The American journal of sports medicine 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41476424 · DOI 10.1177/03635465251357593
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews 2026
Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine. By acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK, peptides exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery. Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF-1 signaling and satellite cell repair. Recovery-enhancing agents such as epithalon, delta sleep-inducing peptide, and pinealon target circadian and mitochondrial regulators, and neuroactive peptides like selank, semax, and dihexa enhance brain-derived n…
open access ↗ · PMID 41490200 · DOI 10.5435/jaaosglobal-d-25-00236
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Preprints.org 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.20944/preprints202512.1011.v3
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports medicine (Auckland, N.Z.) 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · PMID 41966639 · DOI 10.1007/s40279-026-02437-0
Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance — Preprints.org 2026
abstract not reproduced — this record is not open-access, so it is linked rather than copied.
publisher record ↗ · DOI 10.20944/preprints202604.1748.v1
Related
Ipamorelin
gh-secretagogue · 8 citations
Sermorelin
gh-secretagogue · 8 citations
Tesamorelin
gh-secretagogue · 8 citations
GHRP-2
gh-secretagogue · 8 citations
GHRP-6
gh-secretagogue · 7 citations
Hexarelin
gh-secretagogue · 8 citations